Table 2.
Patients' characteristics with the BCSC expression.
BCSC (CD44+ve and CD24−ve) 32 patients | Non-BCSC 44 patients | P | |
---|---|---|---|
Premenopausal | 22 (68.8%) | 21 (47.7%) | 0.1 |
Postmenopausal | 10 (31.2%) | 23 (52.3%) | |
| |||
Grade II | 4 (12.5%) | 26 (59.1%) | 0.001 |
Grade III | 28 (87.5%) | 18 (40.9%) | |
| |||
Luminal A and B | 10 (31.2%) | 30 (68.2%) | 0.006 |
Her2-amplified | 7 (21.9%) | 5 (11.4%) | |
Triple negative | 15 (46.9%) | 9 (20.4%) | |
| |||
CR, PR, and SD | 5 (16.1%) | 22 (51.2%) | 0.003 |
Progressed disease | 26 (83.9%) | 21 (48.8%) |